Calcium Gluconate in Sodium Chloride
These highlights do not include all the information needed to use CALCIUM GLUCONATE IN SODIUM CHLORIDE INJECTION safely and effectively. See full prescribing information for CALCIUM GLUCONATE IN SODIUM CHLORIDE INJECTION.
0deed071-d89d-420e-b4b4-797dce0ad8f0
HUMAN PRESCRIPTION DRUG LABEL
Nov 30, 2023
WG Critical Care, LLC
DUNS: 829274633
Products 2
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
Calcium Gluconate
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (6)
Calcium Gluconate
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (6)
Drug Labeling Information
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
Package/Label Display Panel
NDC 44567-621-02
Novaplus Calcium Gluconate in Sodium Chloride Injection 2,000 mg per 100 mL (20 mg/mL)
INDICATIONS & USAGE SECTION
1 INDICATIONS AND USAGE
Calcium Gluconate in Sodium Chloride Injection is indicated for pediatric and adult patients for the treatment of acute symptomatic hypocalcemia.
Limitations of Use
The safety of Calcium Gluconate in Sodium Chloride Injection for long term use has not been established.
**•**Calcium Gluconate in Sodium Chloride Injection is a form of calcium indicated for pediatric and adult patients for the treatment of acute symptomatic hypocalcemia. (1) (1)
**•**Limitations of Use: The safety of Calcium Gluconate Injection for long term use has not been established. (1) (1)
CONTRAINDICATIONS SECTION
4 CONTRAINDICATIONS
Calcium Gluconate in Sodium Chloride Injection is contraindicated in:
•Hyperca lcemia
• Neonates (28 days of age or younger) receiving ceftriaxone [see Warnings and Precautions (5.2)]
• Hypercalcemia (4) (4)
• Neonates (28 days of age or younger) receiving ceftriaxone (4) (4)
ADVERSE REACTIONS SECTION
6 ADVERSE REACTIONS
The following serious adverse reactions are also described elsewhere in the labeling:
• Arrhythmias with Concomitant Cardiac Glycoside Use [see Warnings and Precautions (5.1)]
• End-Organ Damage due to Intravascular Ceftriaxone-Calcium Precipitates [see Warnings and Precautions (5.2)]
• Tissue Necrosis and Calcinosis [see Warnings and Precautions (5.3)]
• Hypotension, Bradycardia, and Cardiac Arrhythmias [see Warnings and Precautions (5.4)]
• Aluminum toxicity [see Warnings and Precautions (5.5)]
The following adverse reactions associated with the use of calcium gluconate were identified in the literature. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure.
Cardiovascular: Vasodilation, decreased blood pressure, bradycardia, cardiac arrhythmia, syncope, cardiac arrest
Administration site reactions: Local soft tissue inflammation, local necrosis, calcinosis cutis and calcification due to extravasation
The most common adverse events with Calcium Gluconate Injection are local soft tissue inflammation and necrosis, calcinosis cutis and calcification that are related to extravasation. Other adverse events include vasodilation, decreased blood pressure, bradycardia, cardiac arrhythmia, syncope, and cardiac arrest. (6)
**To report SUSPECTED ADVERSE REACTIONS, contactWG Critical Care, LLC at 1-866-562-4708 or FDA at 1-800-FDA-1088 or **www.fda.gov/medwatch.
DRUG INTERACTIONS SECTION
7 DRUG INTERACTIONS
7.1 Cardiac Glycosides
Hypercalcemia increases the risk of digoxin toxicity, while digoxin may be therapeutically ineffective in the presence of hypocalcemia. Synergistic arrhythmias may occur if calcium and cardiac glycosides are administered together. Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.
7.2 Calcium Channel Blockers
Administration of calcium may reduce the response to calcium channel blockers.
7.3 Drugs that may cause Hypercalcemia
Vitamin D, vitamin A, thiazide diuretics, estrogen, calcipotriene and teriparatide administration may cause hypercalcemia. Monitor plasma calcium concentrations in patients taking these drugs concurrently.
• Cardiac Glycoside: Synergistic arrhythmias may occur if calcium and cardiac glycosides are administered together. (7.1) (7)
• Calcium Channel Blockers: Administration of calcium may reduce the response. (7.2) (7)
• Drugs that may cause hypercalcemia: Vitamin D, vitamin A, thiazide diuretics, estrogen, calcipotriene and teriparatide administration may cause hypercalcemia. Monitor plasma calcium concentrations in patients taking these drugs concurrently. (7.3) (7)
DOSAGE FORMS & STRENGTHS SECTION
3 DOSAGE FORMS AND STRENGTHS
Calcium Gluconate in Sodium Chloride Injection is a clear, colorless solution available as:
Injection:
• Calcium gluconate 1,000 mg per 50 mL (20 mg/mL) single-dose bag
• Calcium gluconate 2,000 mg per 100 mL (20 mg/mL) single-dose bag
Injection: (3)
• Calcium gluconate 1,000 mg per 50 mL (20 mg/mL) single-dose bag (3) (3)
• Calcium gluconate 2,000 mg per 100 mL (20 mg/mL) single-dose bag (3) (3)
USE IN SPECIFIC POPULATIONS SECTION
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Risk summary
Limited available data with Calcium Gluconate Injection use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. There are risks to the mother and the fetus associated with hypocalcemia in pregnancy [see Clinical Considerations].
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
Clinical Considerations
Disease-associated maternal risk
Maternal hypocalcemia can result in an increased rate of spontaneous abortion, premature and dysfunctional labor, and possibly preeclampsia.
Fetal/Neonatal adverse reactions
Infants born to mothers with hypocalcemia can have associated fetal and neonatal hyperparathyroidism, which in turn can cause fetal and neonatal skeletal demineralization, subperiosteal bone resorption, osteitis fibrosa cystica and neonatal seizures. Infants born to mothers with hypocalcemia should be carefully monitored for signs of hypocalcemia or hypercalcemia, including neuromuscular irritability, apnea, cyanosis and cardiac rhythm disorders.
8.2 Lactation
Risk summary
Calcium is present in human milk as a natural component of human milk. It is not known whether intravenous administration of Calcium Gluconate in Sodium Chloride Injection can alter calcium concentration in human milk. There are no data on the effects of Calcium Gluconate Injection on the breastfed infant, or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Calcium Gluconate in Sodium Chloride Injection and any potential adverse effects on the breastfed child from Calcium Gluconate in Sodium Chloride Injection or from the underlying maternal condition.
8.4 Pediatric Use
The safety and effectiveness of Calcium Gluconate in Sodium Chloride Injection have been established in pediatric patients for the treatment of acute, symptomatic hypocalcemia.
Pediatric approval for Calcium Gluconate in Sodium Chloride Injection, including doses, is not based on adequate and well-controlled clinical studies. Safety and dosing recommendations in pediatric patients are based on published literature and clinical experience [see Dosage and Administration (2.2)].
Concomitant use of ceftriaxone and Calcium Gluconate in Sodium Chloride Injection is contraindicated in neonates (28 days of age or younger) due to reports of fatal outcomes associated with the presence of lung and kidney ceftriaxone-calcium precipitates. In patients older than 28 days of age, ceftriaxone and Calcium Gluconate Injection may be administered sequentially, provided the infusion lines are thoroughly flushed between infusions with a compatible fluid [see Contraindications (4) and Warnings and Precautions (5.2)]. This product contains up to 25 mcg/L aluminum which may be toxic, particularly for premature neonates due to immature renal function. Parenteral administration of aluminum greater than 4 mcg/kg/day to 5 mcg/kg/day is associated with central nervous system and bone toxicity [see Warnings and Precautions (5.5)].
8.5 Geriatric Use
In general dose selection for an elderly patient should start at the lowest dose of the recommended dose range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
8.6 Renal Impairment
For patients with renal impairment, initiate Calcium Gluconate in Sodium Chloride Injection at the lowest dose of the recommended dose ranges across all age groups. Monitor serum calcium levels every 4 hours [see Dosage and Administration (2.4)].
8.7 Hepatic Impairment
Hepatic function does not impact the availability of ionized calcium after calcium gluconate intravenous administration. Dose adjustment in hepatically impaired patients may not be necessary.
• Geriatric use: Dosing in elderly patients should be cautious, usually starting at the low end of the dosage range. (8.5) (8)
• Renal impairment: Initiate with the lower limit of the dosage range and monitor serum calcium levels every 4 hours. (8.6, 2.4) (8)
OVERDOSAGE SECTION
10 OVERDOSAGE
Overdosage of Calcium Gluconate in Sodium Chloride Injection may result in hypercalcemia. Symptoms of hypercalcemia typically develop when the total serum calcium concentration is ≥12 mg/dL. Neurologic symptoms include depression, weakness, fatigue, and confusion at lower levels, with patients experiencing hallucinations, disorientation, hypotonicity, seizures, and coma. Effects on the kidney include diminished ability to concentrate urine and diuresis.
If overdose of Calcium Gluconate in Sodium Chloride Injection occurs immediately discontinue administration and provide supportive treatments to restore intravascular volume as well as promote calcium excretion in the urine if necessary.
NONCLINICAL TOXICOLOGY SECTION
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Long-term studies in animals have not been conducted to evaluate the carcinogenic potential of Calcium Gluconate in Sodium Chloride Injection. Calcium gluconate was not mutagenic with or without metabolic activation in the Ames test with Salmonella typhimurium (strains TA-1535, TA-1537, and TA-1538) or Saccharomyces cerevisiae (Strain D4). Fertility studies in animals have not been conducted with calcium gluconate administered by the intravenous route.
HOW SUPPLIED SECTION
16 HOW SUPPLIED/STORAGE AND HANDLING
Calcium Gluconate in Sodium Chloride Injection is a clear, colorless solution supplied in single-dose bags with an aluminum overwrap available as:
|
Total Strength per Total Volume |
Strength per mL |
24 single-dose bags NDC |
Bag and Overwrap NDC |
|
1,000 mg per 50 mL |
20 mg/mL |
44567-620-84* |
44567-620-02 |
|
2,000 mg per 100 mL |
20 mg/mL |
44567-621-84 |
44567-621-02 |
*partial fill container 50 mL volume in a 100 mL container.
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Do not freeze. Product should be used within 60 days of removal from aluminum overwrap.
Preservative-free. Discard any unused portion in the single-dose bag immediately.
DOSAGE & ADMINISTRATION SECTION
2 DOSAGE AND ADMINISTRATION
2.1 Important Administration Instructions
See Table 1 for amounts of elemental calcium in Calcium Gluconate in Sodium Chloride Injection.
Table 1. Amounts of Calcium Gluconate and Elemental Calcium
|
Total Strength per Total Volume |
Strength per mL |
Elemental Calcium (mg) per mL |
Elemental Calcium (mEq) per mL |
Total Amount of Elemental Calcium (mg) per Total Volume |
Total Amount of Elemental Calcium (mEq) per Total Volume |
|
1,000 mg per 50 mL |
20 mg/mL |
1.86 mg |
0.093 mEq |
93 mg per 50 mL |
4.65 mEq per 50 mL |
|
1,000 mg per 100 mL |
10 mg/mL |
0.93 mg |
0.0465 mEq |
93 mg per 100 mL |
4.65 mEq per 100 mL |
|
2,000 mg per 100 mL |
20 mg/mL |
1.86 mg |
0.093 mEq |
186 mg per 100 mL |
9.3 mEq per 100 mL |
•
Do not dilute Calcium Gluconate in Sodium Chloride Injection prior to use. Any unused portion should be discarded.
•
Inspect Calcium Gluconate in Sodium Chloride Injection visually prior to administration. The solution should appear clear and colorless. Do not administer if there is particulate matter or discoloration.
•
Administer Calcium Gluconate in Sodium Chloride Injection intravenously via a secure intravenous line to avoid calcinosis cutis and tissue necrosis [see Warnings and Precautions (5.3)].
Administer Calcium Gluconate in Sodium Chloride Injection by continuous infusion at the rate recommended in Table 1 [see Dosage and Administration (2.2)] and monitor patients, vitals, calcium and ECG during the infusion [see Warnings and Precautions (5.4)].
2.2 Recommended Dosage
Individualize the dose of Calcium Gluconate in Sodium Chloride Injection within the recommended range depending on the severity of symptoms of hypocalcemia, the serum calcium level, and the acuity of onset of hypocalcemia.
Table 2 provides dosing recommendations for Calcium Gluconate in Sodium Chloride Injection in mg of calcium gluconate for neonates, pediatric and adult patients.
Table 2. Dosing Recommendations in mg of Calcium Gluconate for Neonate, Pediatric, and Adult Patients
|
Patient****Population |
Initial Dose |
Subsequent Doses (if needed) | |
|
Bolus |
Continuous Infusion | ||
|
Neonate (less than****1 month to 1 month) |
100 mg/kg to 200 mg/kg |
100 mg/kg to 200 mg/kg every 6 hours |
Initiate at 17 mg/kg/hour to 33 mg/kg/hour |
|
Pediatric (greater than 1 month to less than 17 years) |
29 mg/kg to 60 mg/kg |
29 mg/kg to 60 mg/kg every 6 hours |
Initiate at 8 mg/kg/hour to 13 mg/kg/hour |
|
Adult (17 years and greater) |
1,000 mg to 2,000 mg |
1,000 mg to 2,000 mg every 6 hours |
Initiate at 5.4 mg/kg/hour to 21.5 mg/kg/hour |
|
For bolus administration, DO NOT exceed an infusion rate of: For continuous infusions, adjust rate as needed based on serum calcium levels |
2.3 Serum Calcium Monitoring
Measure serum calcium every 4 to 6 hours during intermittent infusions with Calcium Gluconate in Sodium Chloride Injection and measure serum calcium every 1 to 4 hours during continuous infusion.
2.4 Dosage in Renal Impairment
For patients with renal impairment, initiate Calcium Gluconate in Sodium Chloride Injection at the lowest dose of the recommended dose ranges for all age groups and monitor serum calcium levels every 4 hours.
2.5 Drug Incompatibilities
• Do not mix Calcium Gluconate in Sodium Chloride Injection with ceftriaxone. Concurrent use of intravenous ceftriaxone and Calcium Gluconate in Sodium Chloride Injection can lead to the formation of ceftriaxone-calcium precipitates. Concomitant use of ceftriaxone and intravenous calcium- containing products is contraindicated in neonates (28 days of age or younger) [see Contraindications (4)]. In patients older than 28 days of age, ceftriaxone and calcium-containing products may be administered sequentially, provided the infusion lines are thoroughly flushed between infusions with a compatible fluid. Ceftriaxone must not be administered simultaneously with intravenous calcium-containing solutions via a Y-site in any age group [see Warnings and Precautions (5.2), Drug Interactions (7.3)].
• Do not mix Calcium Gluconate in Sodium Chloride Injection with fluids containing bicarbonate or phosphate. Calcium Gluconate Injection is not physically compatible with fluids containing phosphate or bicarbonate. Precipitation may result if mixed.
• Do not mix Calcium Gluconate in Sodium Chloride Injection with minocycline injection. Calcium complexes minocycline rendering it inactive.
• Administer intravenously (bolus or continuous infusion) via a secure intravenous line (2.1) (2)
• See Full Prescribing Information (FPI) for administration rates, and appropriate monitoring (2.1) (2)
• Do not dilute Calcium Gluconate in Sodium Chloride Injection prior to use. Any unused portion should be discarded (2.1) (2)
• Individualize the dose within the recommended range in adults and pediatric patients depending on the severity of symptoms of hypocalcemia, the serum calcium level, and the acuity of onset of hypocalcemia. See Table 1 in the FPI for dosing recommendations in mg of calcium gluconate for neonates, pediatric and adult patients. (2.2) (2)
• Measure serum calcium during intermittent infusions every 4 to 6 hours and during continuous infusion every 1 to 4 hours. (2.3) (2)
• Calcium Gluconate Injection is not physically compatible with fluids containing phosphate or bicarbonate. Precipitation may result if mixed. See FPI for all drug incompatibilities. (2.5) (2)
CLINICAL PHARMACOLOGY SECTION
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Intravenous administration of calcium gluconate increases serum ionized calcium level. Calcium gluconate dissociates into ionized calcium in plasma. Ionized calcium and gluconate are constituents of body fluids.
12.3 Pharmacokinetics
Absorption
Calcium Gluconate Injection is 100% bioavailable following intravenous injection.
Metabolism
Calcium itself does not undergo direct metabolism. The release of ionized calcium from intravenous administration of calcium gluconate is direct and does not seem to be affected by the first pass through the liver.
Distribution
Calcium in the body is distributed mainly in skeleton (99%). Only 1% of the total body calcium is distributed within the extracellular fluids and soft tissues. About 50% of total serum calcium is in the ionized form and represents the biologically active part. 8% to 10% serum calcium is bound to organic and inorganic acid and approximately 40% is protein-bound (primarily to albumin).
Elimination
Studies have shown a relationship between urinary calcium excretion and the intravenous administration of calcium gluconate, with a significant increase in urinary calcium excretion observed after the intravenous administration of calcium gluconate.
DESCRIPTION SECTION
11 DESCRIPTION
Calcium Gluconate in Sodium Chloride Injection is a sterile, preservative- free, nonpyrogenic solution of calcium gluconate, a form of calcium, for intravenous use.
Calcium Gluconate is calcium D-gluconate (1:2) monohydrate. The structural formula is:
Molecular formula: C12H22CaO14• H2O
Molecular weight: 448.39
Solubility in water: 3.5 g/100 mL at 25°C
Calcium Gluconate in Sodium Chloride Injection is available as 1,000 mg per 50 mL (equivalent to 18.8 mg per mL calcium gluconate anhydrous), 2,000 mg per 100 mL (equivalent to 18.8 mg per mL calcium gluconate anhydrous) in single- dose bags.
Table 3. Calcium Gluconate Formulations
|
1,000 mg per 50 mL |
2,000 mg per 100 mL | |
|
Calcium Gluconate |
20 mg per mL |
20 mg per mL |
|
Elemental Calcium |
1.86 mg per mL |
1.86 mg per mL |
|
Sodium Chloride |
6.75 mg per mL |
6.75 mg per mL |
|
Hydrochloric Acid or Sodium Hydroxide |
pH adjusted 6.0 to 8.2 |
INFORMATION FOR PATIENTS SECTION
17 PATIENT COUNSELING INFORMATION
Inform patients of the risks associated with infusion of Calcium Gluconate in Sodium Chloride Injection including local tissue inflammation, local necrosis and calcinosis. [see Warnings and Precautions (5.3)].
Manufactured for:
WG Critical Care, LLC
Paramus, NJ 07652
Made in Switzerland
U.S. Patent Numbers 10,342,813 and 10,130,646
Novaplus is a registered trademark of Vizient, Inc.